Regulatory & Policy

Aprea Therapeutics secures Australian and Japanese patents for WEE1 and ATR inhibitor cancer programs

Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company headquartered in the US, announced the expansion of its global...

Edited by Robert McTiernan··6 min read

Aprea Therapeutics receives patent grants in Australia and Japan for DNA damage response cancer therapeutics

Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company headquartered in the US, announced the expansion of its global intellectual property estate with new patents granted in 2025 in Australia and Japan covering its WEE1 and ATR inhibitor programs, respectively. The Aprea Therapeutics patent portfolio now spans composition of matter, pharmaceutical formulation, and method-of-treatment claims across both programs, with core patent families expected to provide exclusivity into 2045. The grants reinforce the company's position in DNA damage response cancer therapeutics, a field in which multiple competing programs are advancing through early and mid-stage clinical development.

The Australian patent covers the WEE1 inhibitor pipeline anchored by APR-1051, while the Japanese patent covers the ATR program centered on ATRN-119. In total, the ATR inhibitor patent estate includes four issued US patents, one pending US application, 21 granted patents internationally, and 15 pending international applications. The WEE1 portfolio includes one provisional US patent application, two pending US applications, one issued Australian patent, and 13 pending applications outside the US. Aprea also disclosed that it filed provisional applications in the US in 2025 covering macrocyclic inhibitors of an undisclosed DDR target, signaling a third axis in its cancer drug patent portfolio.

Mechanism and clinical development status of the Aprea Therapeutics DDR programs

Both APR-1051 and ATRN-119 operate within the DNA damage response pathway, a network of kinases and signaling proteins that cancer cells co-opt to survive replication stress and therapy-induced DNA damage. WEE1 kinase functions as a negative regulator of cyclin-dependent kinases CDK1 and CDK2, enforcing the S-phase and G2/M cell-cycle checkpoints. By inhibiting WEE1, APR-1051 is designed to release this brake on cell-cycle progression, forcing tumor cells with damaged or incompletely replicated DNA into premature mitosis, a process that can trigger replication catastrophe and cell death. This vulnerability is particularly pronounced in tumors harboring p53 mutations, which are already deficient in G1 checkpoint control and therefore rely more heavily on the G2/M checkpoint for survival.

ATR kinase sits upstream in the same pathway, activated by single-stranded DNA exposed at stalled replication forks. ATR signals through CHK1 to slow replication origin firing, stabilize forks, and impose S/G2 checkpoints. Tumors with high levels of oncogene-driven replication stress or with loss-of-function alterations in other DDR genes such as ATM can become dependent on ATR signaling, creating a therapeutic window for ATR inhibitors like ATRN-119.

APR-1051 is currently being evaluated in the ACESOT-1051 Phase I clinical trial (NCT06260514) in patients with advanced or metastatic solid tumors harboring certain cancer-associated gene alterations. The company has disclosed early clinical signals, including an unconfirmed partial response in a patient with PPP2R1A-mutated uterine serous carcinoma and observations of stable disease in early dose-escalation cohorts. Multiple data readouts are anticipated in 2026.

ATRN-119 is being evaluated in the ABOYA-119 Phase I/Phase II clinical trial (NCT04905914) as monotherapy in patients with advanced solid tumors. The company has established a recommended Phase II dose and presented updated clinical data at scientific conferences. Specific clinical results from the Phase II expansion cohorts remain undisclosed in the patent announcement. Both assets remain investigational; neither has received regulatory approval in any jurisdiction.

Context and competitive landscape

The Aprea Therapeutics patent grants arrive at a time of active clinical development across the WEE1 inhibitor pipeline and ATR inhibitor space, with several companies advancing competing molecules through early and mid-stage trials.

The AllSci BriefSystematic R&D and deal news. Daily.

In the WEE1 inhibitor class, the most extensively studied compound is adavosertib (AZD1775), originally developed by AstraZeneca (United Kingdom). Adavosertib has been evaluated in numerous Phase I and Phase II trials both as monotherapy (NCT02482311) and in combination with platinum chemotherapy in settings such as TP53-mutant ovarian cancer (NCT01164995). While it has generated a substantial clinical dataset establishing proof of concept for WEE1 inhibition, adavosertib has not advanced to registration and its development trajectory has been shaped by tolerability constraints. Azenosertib (ZN-c3), developed by Zentalis Pharmaceuticals (US), represents a next-generation WEE1 inhibitor currently in a Phase II trial in platinum-resistant ovarian cancer selected for Cyclin E1 overexpression (NCT05128825). Azenosertib's biomarker-driven design reflects an effort to improve the therapeutic index relative to earlier WEE1 inhibitors.

Among ATR inhibitors, camonsertib (RP-3500), developed by Repare Therapeutics (Canada), has established itself as a clinical benchmark through its TRESR Phase I program (NCT04497116), which enrolled patients selected for DDR loss-of-function alterations. Results published in Nature Medicine in 2023 described the biomarker strategy and dose-optimization approach, including intermittent scheduling designed to manage on-target anemia, a class-wide tolerability challenge for ATR inhibitors. Ceralasertib (AZD6738), developed by AstraZeneca (United Kingdom), has one of the broadest clinical footprints in the ATR class, with a multi-arm Phase II umbrella trial (NCT03682289) evaluating combinations with olaparib, durvalumab, and other agents across multiple tumor types. Elimusertib (BAY 1895344), developed by Bayer (Germany), has completed a first-in-human Phase I trial (NCT03188965) and is being explored in NCI-sponsored and company-led combination studies, including a trial combining elimusertib with gemcitabine (NCT04616534).

Beyond direct target competitors, adjacent DDR checkpoint approaches compete for similar patient populations. Prexasertib, a CHK1/CHK2 inhibitor with Phase II data in ovarian cancer (NCT02873975), occupies a mechanistically overlapping niche. Repare Therapeutics is also advancing lunresertib, a PKMYT1 inhibitor, in combination with camonsertib in the MYTHIC Phase I trial (NCT04855656), targeting CCNE1-amplified tumors through a dual-checkpoint strategy.

Aprea's approach with both APR-1051 and ATRN-119 emphasizes biomarker selection, enrolling patients with specific cancer-associated gene alterations or DDR pathway defects. This precision strategy contrasts with broader cytotoxic or immunotherapy-based approaches to the same tumor types. The two approved products most relevant as functional benchmarks for the same patient populations are olaparib (AstraZeneca, United Kingdom), a PARP inhibitor approved by the US FDA for multiple BRCA-mutated and HRD-positive solid tumor indications, and teplizumab-mzwv is not relevant here; rather, niraparib (GSK, United Kingdom), another PARP inhibitor approved in ovarian cancer maintenance settings. Both PARP inhibitors address overlapping DDR-deficient populations but through a distinct mechanism, trapping PARP at single-strand break sites rather than abrogating cell-cycle checkpoints. Aprea's Therapeutics DDR programs would need to demonstrate clinical differentiation, whether through activity in PARP inhibitor-resistant settings, distinct biomarker-defined subgroups, or combination strategies that extend beyond what current PARP-based regimens achieve.

The patent grants in Australia and Japan do not alter the clinical risk profile of either program but extend the geographic scope of exclusivity protection for any future commercial product. The pending applications, if granted across remaining jurisdictions, would establish a layered intellectual property position spanning new chemical entities, formulations, and methods of use through the mid-2040s.

  • Adavosertib (AZD1775), AstraZeneca (United Kingdom): WEE1 inhibitor, Phase I/Phase II — NCT02482311
  • Azenosertib (ZN-c3), Zentalis Pharmaceuticals (US): WEE1 inhibitor, Phase II — NCT05128825
  • Camonsertib (RP-3500), Repare Therapeutics (Canada): ATR inhibitor, Phase I — NCT04497116
  • Ceralasertib (AZD6738), AstraZeneca (United Kingdom): ATR inhibitor, Phase I/Phase II — NCT03682289
  • Elimusertib (BAY 1895344), Bayer (Germany): ATR inhibitor, Phase I — NCT03188965
  • Prexasertib, historical development by Eli Lilly (US): CHK1/CHK2 inhibitor, Phase II — NCT02873975
  • Lunresertib + camonsertib, Repare Therapeutics (Canada): PKMYT1 + ATR inhibitor combination, Phase I — NCT04855656

Spot something wrong? Report an issue with this article